文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

碳青霉烯类抗生素用于医院获得性肺炎的经验性治疗:系统评价与Meta分析

Carbapenem Antibiotics for the Empiric Treatment of Nosocomial Pneumonia: A Systematic Review and Meta-analysis.
PubMed 文献 · Chest · 2020-10-23
一句话结论在HAP/VAP经验性治疗中,含碳青霉烯方案较非碳青霉烯方案降低全因死亡率(RR 0.84),但高APACHE II评分者无获益,且耐药趋势值得关注。

该系统评价与Meta分析纳入20项RCT、共5489例HAP/VAP患者,比较含碳青霉烯与非碳青霉烯经验性方案。按病情分层,仅APACHE II<14和14-17组显示死亡获益。高疾病严重度试验中未见死亡获益,且死亡率差异主要见于以头孢他啶为对照的研究。

适用人群与场景

  • 纳入比较含碳青霉烯与非碳青霉烯经验性方案治疗医院获得性肺炎(HAP)和/或呼吸机相关性肺炎(VAP)的随机对照试验患者,共20项试验、5489例。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及具体药物剂量、给药途径、频次或疗程。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:系统评价与Meta分析,纳入20项RCT、5489例患者,比较含碳青霉烯与非碳青霉烯经验性方案治疗HAP/VAP。
  • 死亡率差异主要见于以头孢他啶为对照的研究。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析(RCT)。
  • 局限:原文未明确列出,但设计上为Meta分析,异质性来源包括对照药物不同(如头孢他啶)及VAP比例差异。

对床旁实践的改变

  • 对于HAP/VAP经验性治疗,含碳青霉烯方案可能降低死亡率,尤其VAP比例高的试验中;但高APACHE II评分(≥18)患者未见死亡获益,不应仅基于死亡率获益在此类人群常规使用。
  • 死亡率获益主要见于以头孢他啶为对照的研究,选择非碳青霉烯对照药物时需考虑此因素。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Previous meta-analyses suggested that treating hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), with empiric carbapenems was associated with lower mortality rates but higher rates of clinical failure for pseudomonal pneumonia. This study was an updated meta-analysis with sensitivity analyses and meta-regression to better understand the impact of carbapenem use in HAP/VAP.

RESEARCH QUESTION: What is the efficacy of carbapenems for empiric treatment of nosocomial pneumonia?

STUDY DESIGN AND METHODS: Databases were searched for randomized controlled studies evaluating empiric treatment for HAP and/or VAP, and studies were included comparing carbapenem- vs non-carbapenem-containing regimens. The primary outcome was all-cause mortality. Secondary outcomes included subgroup stratification and resistance development.

RESULTS: Of 9,140 references, 20 trials enrolling 5,489 patients met inclusion criteria. For mortality, carbapenem use had a risk ratio (RR) of 0.84 (95% CI, 0.74-0.96; P = .01). Stratified according to VAP proportion (< 33%, 33%-66%, and > 66%), RRs were 0.95 (95% CI, 0.77-1.17; P = .66), 0.78 (95% CI, 0.57-1.07; P = .13), and 0.81 (95% CI, 0.65-0.99; P = .04), respectively. Stratified according to severity, only groups with Acute Physiology and Chronic Health Evaluation II scores < 14 and between 14 and 17 showed mortality benefit (RRs of 0.64 [95% CI, 0.45-0.92; P = .01] and 0.77 [95% CI, 0.61-0.97; P = .03]). Meta-regression did not show an association between Pseudomonas prevalence and mortality (P = .44). Carbapenem use showed a trend toward developing resistance (RR, 1.40; 95% CI, 0.95-2.06; P = .09) and a 96% probability of resistance emergence.

INTERPRETATION: Carbapenem-based empiric regimens were associated with lower mortality rates compared with non-carbapenems, largely driven by trials of VAP. The mortality effect was not observed in trials with high disease severity and was not associated with Pseudomonas. The mortality difference was observed mainly in studies that used ceftazidime as control. There was a trend toward increasing resistance associated with carbapenems.

TRIAL REGISTRY: International Prospective Register of Systematic Reviews; No. CRD42018093602; URL: https://www.crd.york.ac.uk/prospero/.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Howatt M, Klompas M, Kalil AC, et al. Carbapenem Antibiotics for the Empiric Treatment of Nosocomial Pneumonia: A Systematic Review and Meta-analysis. Chest. 2020. PMID: 33393468. doi:10.1016/j.chest.2020.10.039

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。